[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"enoxaparin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:enoxaparin":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100543556","association-of-anti-factor-xa-activity-with-venous-thromboembolism-in-critically-ill-patients-100543556",false,"NCT06357403","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients: a Prospective Multicentre Cohort Study","AntiXa-ICU","Inclusion Criteria:\n\n* Age over 18 years at the time of intensive care unit admission\n* Admission to a participating intensive care unit within the last 24 hours\n* Expected discharge is later than 48 hours after enrolment\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE\u002Fkg when given twice daily or of at least 150 IE\u002Fkg when given once daily\n* Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment\n* Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period\n* Estimated life expectancy below 48 hours or comfort terminal care order in place\n* Previously diagnosed heparin-induced thrombocytopenia\n* Pre-operative admission for elective surgery\n* Previous enrolment in the study","ALL","18 Years",{"count":20,"type":21},1300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and\u002For pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:\n\n* What is the association between antiXa and VTE?\n* What is the association between antiXa and symptomatic, respectively incidental, VTE?\n* How is pharmacological anticoagulation with enoxaparin related to measured antiXa?\n* What is the association between antiXa and bleeding complications.\n* What is the incidence of venous thromboembolism in patients treated at an intensive care unit?\n* How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit\u002Fhospital.",[25,26,27],"Thrombosis","Pulmonary Embolism","Enoxaparin","RECRUITING","2026-06-18",{"date":31,"type":32},"2026-06-23","ACTUAL",{"date":34,"type":32},"2024-05-04",{"date":36,"type":21},"2027-08",{"name":38,"class":39},"Medical University of Vienna","OTHER",3]